Strategic Partnerships Identify potential collaboration with contract research organizations and patient advocacy groups in neurodegenerative and neurodevelopmental disorders to accelerate late-stage trials for ANAVEX2-73 and future candidates.

Clinical Trial Opportunities Leverage ongoing and completed Phase 2/3 programs in Alzheimer's, Parkinson's, Rett syndrome, and related CNS conditions to open advisory, data sharing, or co-development discussions with pharma partners seeking late-stage assets.

Financial Readiness With substantial funding and a mid-sized revenue range, target strategic suitors or licensees who can scale manufacturing, distribution, or global regulatory support to monetize late-stage assets efficiently.

Senior Leadership Gap The recent executive leadership changes and interim CEO appointment present an opening for consulting, interim leadership, or collaboration on strategic roadmaps during a transition, while presenting a stable line of communication for BD efforts.

University and Foundation Grants Target opportunities tied to foundation funding and academic grants (e.g., Parkinson’s and Alzheimer’s research funders) to co-sponsor preclinical studies or translational programs that align with ANAVEX2-73 and ANAVEX3-71 mechanisms.